Vericel Corporation (VCEL)
Vericel Corporation (VCEL) Stock Price, Analysis & Data
| Bid | 39.62 |
| Market Cap | 2.23B |
| Revenue (ttm) | 306.3M |
| Net Income (ttm) | 24.22M |
| Beta | 1.07 |
| EPS (ttm) | 0.48 |
| PE Ratio (ttm) | 90.77 |
| Forward PE | 51.5 |
| P/B (ttm) | 6.03 |
| P/S (ttm) | 7.28 |
| Earnings Date | Nov 5, 2026 |
| Ask | 52.78 |
| Volume | 393,543 |
| Avg. Volume (20D) | 579,738 |
| Open | 45.04 |
| Previous Close | 44.26 |
| Day's Range | 42.89 - 46.01 |
| 52-Week Range | 28.95 - 49.32 |
| Analyst | n/a |
| Price Target | 59 (34.06%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-...
Financial Performance
In 2025, Vericel's revenue was 276.26M, an increase of 16.45% compared to the previous year's 237.22M. Earnings were 16.52M, an increase of 59.41%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for VCEL stock is "null". The 12-month stock price forecast is 59, which is upside of 34.06% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
